(Reuters) -British drugmaker GSK said on Wednesday it is restructuring a partnership with German biotech CureVac and will take control of several vaccines the two companies were jointly developing. GSK said it will pay CureVac 400 million euros ($429.44 million) upfront and up to an additional 1.05 billion euros ($1.13 billion) in development, regulatory and sales milestones as well as tiered royalties. The partnership began in 2020 during the COVID-19 pandemic and saw the two companies work together to develop vaccines for infectious diseases using messenger RNA (mRNA) technology.
CureVac N.V. ( NASDAQ:CVAC ) just released its latest quarterly report and things are not looking great. It was a...
CureVac ( NASDAQ:CVAC ) First Quarter 2024 Results Key Financial Results Revenue: €12.4m (up 74% from 1Q 2023). Net...